Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Japanese Clinical Practice Guideline for Diabetes 2016
Masakazu Haneda, Mitsuhiko Noda, Hideki Origasa, et al.
Diabetology International (2018) Vol. 9, Iss. 1, pp. 1-45
Open Access | Times Cited: 295

Showing 1-25 of 295 citing articles:

The Pathophysiology of Gestational Diabetes Mellitus
Jasmine F. Plows, Joanna L. Stanley, Philip N. Baker, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3342-3342
Open Access | Times Cited: 1260
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, et al.
Clinical Journal of the American Society of Nephrology (2020) Vol. 15, Iss. 12, pp. 1715-1727
Open Access | Times Cited: 170
Japanese Clinical Practice Guideline for Diabetes 2016
Masakazu Haneda, Mitsuhiko Noda, Hideki Origasa, et al.
Journal of Diabetes Investigation (2018) Vol. 9, Iss. 3, pp. 657-697
Open Access | Times Cited: 167
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 5, pp. 377-391
Open Access | Times Cited: 157
Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 5, pp. 392-406
Closed Access | Times Cited: 146
Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial
Eri Wada, Takeshi Onoue, Tomoko Kobayashi, et al.
BMJ Open Diabetes Research & Care (2020) Vol. 8, Iss. 1, pp. e001115-e001115
Open Access | Times Cited: 111
Retrospective nationwide study on the trends in first‐line antidiabetic medication for patients with type 2 diabetes in Japan
Ryotaro Bouchi, Takehiro Sugiyama, Atsushi Goto, et al.
Journal of Diabetes Investigation (2021) Vol. 13, Iss. 2, pp. 280-291
Open Access | Times Cited: 95
Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
Sadayoshi Ito, Kenichi Shikata, Masaomi Nangaku, et al.
Clinical Journal of the American Society of Nephrology (2019) Vol. 14, Iss. 8, pp. 1161-1172
Open Access | Times Cited: 94
Indirect insulin resistance detection: Current clinical trends and laboratory limitations
Sylwia Płaczkowska, Lilla Pawlik-Sobecka, Izabela Kokot, et al.
Biomedical Papers (2019) Vol. 163, Iss. 3, pp. 187-199
Open Access | Times Cited: 84
JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases
Masakazu Yamagishi, Nagara Tamaki, Takashi Akasaka, et al.
Circulation Journal (2021) Vol. 85, Iss. 4, pp. 402-572
Open Access | Times Cited: 74
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial
Julie Dubourg, Pascale Fouqueray, Carole Thang, et al.
Diabetes Care (2021) Vol. 44, Iss. 4, pp. 952-959
Open Access | Times Cited: 70
Recently updated global diabetic retinopathy screening guidelines: commonalities, differences, and future possibilities
Taraprasad Das, Brijesh Takkar, Sobha Sivaprasad, et al.
Eye (2021) Vol. 35, Iss. 10, pp. 2685-2698
Open Access | Times Cited: 62
Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review
Rishi Raj, Rahul Mishra, Nivedita Jha, et al.
BMJ Open Diabetes Research & Care (2022) Vol. 10, Iss. 1, pp. e002573-e002573
Open Access | Times Cited: 49
Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial
Ling Qu, Xiao‐chun Liang, Guoqing Tian, et al.
Diabetes Care (2021) Vol. 44, Iss. 6, pp. 1324-1333
Open Access | Times Cited: 40
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial
Julie Dubourg, Kohjiro Ueki, Jean‐Marie Grouin, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 3, pp. 800-810
Open Access | Times Cited: 49
Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: an analysis of 1,121,359 cases from the nationwide databases
Mitsuyoshi Takahara, Osamu Iida, Shun Kohsaka, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 46
Gestational Diabetes Mellitus Screening and Diagnosis
Ümit Yasemin Sert, A. Seval Özgü-Erdinç
Advances in experimental medicine and biology (2020), pp. 231-255
Closed Access | Times Cited: 46
Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second‐line therapy: Results from the global DISCOVER study programme
Antonio Nicolucci, B Charbonnel, Marília Brito Gomes, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 11, pp. 2474-2485
Open Access | Times Cited: 43
Sorbitol Is a Severity Biomarker for PMM2‐CDG with Therapeutic Implications
Anna N. Ligezka, Silvia Radenkovic, Mayank Saraswat, et al.
Annals of Neurology (2021) Vol. 90, Iss. 6, pp. 887-900
Open Access | Times Cited: 40
Management of Gestational Diabetes Mellitus
Z. Aslı Oskovi-Kaplan, A. Seval Özgü-Erdinç
Advances in experimental medicine and biology (2020), pp. 257-272
Closed Access | Times Cited: 39
Associations between continuous glucose monitoring-derived metrics and diabetic retinopathy and albuminuria in patients with type 2 diabetes
Satomi Wakasugi, Tomoya Mita, Naoto Katakami, et al.
BMJ Open Diabetes Research & Care (2021) Vol. 9, Iss. 1, pp. e001923-e001923
Open Access | Times Cited: 33
Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Mala Dharmalingam, Surendra Kumar Sharma, Ved Prakash, et al.
Cureus (2024)
Open Access | Times Cited: 4
Circadian variation in patients with acute heart failure with preserved ejection fraction
Kenichi Matsushita, Kazumasa Harada, Takahiro Jimba, et al.
Minerva Cardiology and Angiology (2025) Vol. 73, Iss. 2
Closed Access
Age group differences in association between IADL decline and depressive symptoms in community-dwelling elderly
Eri Kiyoshige, Mai Kabayama, Yasuyuki Gondo, et al.
BMC Geriatrics (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 42
The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
Mads Frederik Rasmussen
Diabetology International (2020) Vol. 11, Iss. 2, pp. 76-86
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top